High-dose intravenous immunoglobulin in the treatment of adult patients with bullous pemphigoid

European Journal of Dermatology

Volumn 22, Issue 3, 2012, Pages 363-369

  Gaitanis, Georgios ^a   Alexis, Ioannis ^a   Pelidou, Sygkliti Henrietta ^a   Refidaff, Cref ^a   Elisaf, Moses S ^a   Bassukas, Ioannis D ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Adult; Bullous pemphigoid; Intravenous immunoglobulin; Treatment

Indexed keywords

AZATHIOPRINE; CLINDAMYCIN; CORTICOSTEROID; CYCLOSPORIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTRATECT; METHOTREXATE; METHYLPREDNISOLONE; MOMETASONE FUROATE; RITUXIMAB; TIMENTIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLISTER; BULLOUS PEMPHIGOID; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; EARLY INTERVENTION; FEMALE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTIPLE CYCLE TREATMENT; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PANCYTOPENIA; PROGNOSIS; REMISSION; SEPSIS; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MIDDLE AGED; PEMPHIGOID, BULLOUS; PROGNOSIS;

EID: 84863224822     PISSN: 11671122     EISSN: 19524013     Source Type: Journal    
DOI: 10.1684/ejd.2012.1717     Document Type: Article

References (28)

1. Wojnarowska F, Kirtschig G, Highet AS, et al. Guidelines for the management of bullous pemphigoid. Br J Dermatol 2002; 147: 214-221.
2. Khumalo NP, Murrell DF, Wojnarowska F, Kirtschig G. A systematic review of treatments for bullous pemphigoid. Arch Dermatol 2002;138:385-389.
3. Joly P, Roujeau JC, Benichou J, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol 2009;129:1681-1687.
4. Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome in patients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol 2002;138:903-908.
5. Roujeau JC, Lok C, Bastuji-Garin S, et al. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol 1998;134:465-469.
6. Savin JA. Some factors affecting prognosis in pemphigus vulgaris and pemphigoid. Br J Dermatol 1981; 104: 415-420.
7. Enk A. Guidelines on the use of high-dose intravenous immunoglobulin in dermatology. Eur J Dermatol 2009; 19: 90-98.
8. Godard W, Roujeau JC, Guillot B, et al. Bullous pemphigoid and intravenous gammaglobulin. Ann Intern Med 1985; 103: 964-965.
9. Smith SD, Dennington PM, Cooper A. The use of intravenous immunoglobulin for treatment of dermatological conditions in Australia: A review. Australas J Dermatol 2010; 51: 227-237.
10. Gürcan HM, Jeph S, Ahmed AR. Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for its efficacy and safety. Am J Clin Dermatol 2010; 11: 315-326.
11. Skandalis K, Spirova M, Gaitanis G, et al. Drug-induced bullous pemphigoid in diabetes mellitus patients receiving dipeptidyl peptidase-IV inhibitors plus metformin. J Eur Acad Dermatol Venereol 2012; 26(2): 249-253.
12. Tsiriopoulos I, Kiorpelidou D, Gaitanis G, et al. Lower urinary tract involvement in patients with newly diagnosed autoimmune bullous dermatoses: an urethrocystoscopic study. Am J Med Sci 2010; 340:109-113.
13. Ahmed AR. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol 2001; 45: 825-835.
14. Tappeiner G, Steiner A. High-dosage intravenous gamma globulin: therapeutic failure in pemphigus and pemphigoid. J Am Acad Dermatol 1989; 20: 684-685.
15. Beckers RC, Brand A, Vermeer BJ, Boom BW. Adjuvant high-dose intravenous gammaglobulin in the treatment of pemphigus and bullous pemphigoid: experience in six patients. Br J Dermatol 1995; 133: 289-293.
16. Harman KE, Black MM. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br J Dermatol 1999; 140: 865-874.
17. Ahmed AR. Use of intravenous immunoglobulin therapy in autoimmune blistering diseases. Int Immunopharmacol 2006; 6: 557-578.
18. Nanda A, Al-Saeid K, Al-Sabah H, et al. Clinicoepidemiological features and course of 43 cases of bullous pemphigoid in Kuwait. Clin Exp Dermatol 2006;31:339-342.
19. Czernik A, Bystryn JC. Improvement of intravenous immunoglobulin therapy for bullous pemphigoid by adding immunosuppressive agents: marked improvement in depletion of circulating autoantibo-dies. Arch Dermatol 2008; 144: 658-661.
20. Wetter DA, Davis MD, Yiannias JA, et al. Effectiveness of intravenous immunoglobulin therapy for skin disease other than toxic epidermal necrolysis: a retrospective review of Mayo Clinic experience. Mayo Clin Proc 2005; 80: 41-47.
21. Jolles S. High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders. Clin Exp Immunol 2002; 129:385-389.
22. Ahmed AR, Colon JE. Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy. Arch Dermatol 2001; 137:1181-1189.
23. Amagai M, Ikeda S, Shimizu H, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009;60:595-603.
24. Ishii N, Hashimoto T, Zillikens D, Ludwig RJ. High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases. Clin Rev Allergy Immunol 2010; 38: 186-195.
25. Sami N, Ali S, Bhol KC, Ahmed AR. Influence of intravenous immunoglobulin therapy on autoantibody titres to BP Ag1 and BP Ag2 in patients with bullous pemphigoid. J Eur Acad Dermatol Venereol 2003; 17:641-645.
26. Cortés B, Marazza G, Naldi L, et al. Mortality of bullous pemphigoid in Switzerland: a prospective study. Br J Dermatol 2011; 165:368-374.
27. Parker S, Dyson S, Brisman S et al. Mortality of bullous pemphigoid: An evaluation of 223 patients and comparison with the mortality in the general population in the United States. J Am Acad Dermatol 2008; 59: 582-588.
28. Bernard P, Reguiai Z, Tancrede-Bohin E et al. Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study. Arch Dermatol 2009; 145: 537-542.